What is the Return on Assets (ROA) of Exelixis this year?
The Return on Assets (ROA) of Exelixis is 0.07 undefined this year.
Exelixis ROA 2024
Exelixis ROA
0.07
Ticker
EXEL
ISIN
US30161Q1040
WKN
936718
In 2024, Exelixis's return on assets (ROA) was 0.07, a 18.97% increase from the 0.06 ROA in the previous year.
Exelixis Aktienanalyse
What does Exelixis do?
Exelixis Inc. is a biopharmaceutical company that specializes in researching and developing drugs for various types of cancer. The company was founded in 1994 and is headquartered in Alameda, California. It has brought several drugs to the market over the years that have had a positive impact on thousands of patients. The company's founders, Corey Goodman, George Scangos, and John Walker, previously worked at Genentech and decided to start their own company to focus on cancer research and drug development. Exelixis Inc. has had numerous successes since its inception, including the development of Cabozantinib, a drug used to treat various types of cancer such as thyroid cancer, kidney cancer, and advanced prostate cancer. The company also has several drug candidates in clinical testing. Its business model revolves around researching and developing drugs that target proteins and signaling pathways overactivated in cancer cells. Exelixis Inc. often collaborates with other companies in the pharmaceutical industry to share development costs and risks. The company is divided into different divisions to treat various cancer types, including kidney, liver, thyroid, and lung cancer. One of its significant milestones was the approval of Cabozantinib by the FDA in 2012 for the treatment of advanced kidney and thyroid cancer. The drug has since been approved in other countries and has been successful in treating different types of cancer. Exelixis Inc. is dedicated to developing better and more effective cancer drugs to help patients. It works closely with doctors, researchers, and other pharmaceutical companies to constantly explore new approaches to combat cancer cells. In summary, Exelixis Inc. is a leading player in the research and development of drugs for various types of cancer. It has a track record of approved drugs and a pipeline of innovative drug candidates. The company's goal is to help cancer patients and contribute to improving people's health. Exelixis ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding Exelixis's Return on Assets (ROA)
Exelixis's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing Exelixis's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider Exelixis's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in Exelixis’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about Exelixis stock
What was the ROA of Exelixis compared to the previous year?
The ROA of Exelixis has increased by 18.97% compared to the previous year.
What consequences do high ROA have for investors of Exelixis?
A high ROA is advantageous for investors of Exelixis, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in Exelixis?
A low ROA can be unfavorable for investors of Exelixis as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of Exelixis affect the company?
An increase in ROA of Exelixis can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of Exelixis impact the company?
A reduction in the ROA of Exelixis can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of Exelixis?
Some factors that can influence the ROA of Exelixis include revenue, operating costs, asset structure, and industry average.
Why is the ROA of Exelixis important for investors?
The ROA of Exelixis is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can Exelixis take to improve ROA?
To improve ROA, Exelixis can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does Exelixis pay?
Over the past 12 months, Exelixis paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Exelixis is expected to pay a dividend of 0 USD.
What is the dividend yield of Exelixis?
The current dividend yield of Exelixis is .
When does Exelixis pay dividends?
Exelixis pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Exelixis?
Exelixis paid dividends every year for the past 0 years.
What is the dividend of Exelixis?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Exelixis located?
Exelixis is assigned to the 'Health' sector.
Wann musste ich die Aktien von Exelixis kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Exelixis from 7/31/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/31/2024.
When did Exelixis pay the last dividend?
The last dividend was paid out on 7/31/2024.
What was the dividend of Exelixis in the year 2023?
In the year 2023, Exelixis distributed 0 USD as dividends.
In which currency does Exelixis pay out the dividend?
The dividends of Exelixis are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Exelixis
Our stock analysis for Exelixis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Exelixis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
